Pharmaceutical combination for cancer treatment

Abstract

A method for treating cancer includes administering to a subject an effective amount of tyrosine kinase inhibitor and an effective amount of Clostridium butyricum MIYAIRI 588 deposited as (FERM BP-2789) or a culture thereof in combination. In one embodiment, the Clostridium butyricum MIYAIRI 588 is a viable bacterium. In one embodiment, the tyrosine kinase inhibitor is at least one of an EGFR tyrosine kinase inhibitor, a c-kit receptor tyrosine kinase inhibitor, a BCR-ABL tyrosine kinase inhibitor, or a multikinase inhibitor.

Dependencies are inferred from the claim text.